Several drugmakers expressed interest in acquiring Bayer's dermatology business. The Leverkusen, Germany-based company is looking to sell off some of its assets in preparation of its $66 billion acquisition of Monsanto, reported Reuters.
Interested candidates include Canonsburg, Pa.-based Mylan, Ahmedabad, India-based Torrent Pharmaceuticals and Petah Tikva, Israel-based Teva Pharmaceuticals.
Bayer's dermatology products include Desonate, used to treat eczema, and Finacea, a treatment for rosacea. The business could sell for as much as $1.1 billion, according to the report.
More articles on supply chain:
Amgen, Arrowhead Pharma to collaborate on gene-silencing drugs
Uber to develop technology to connect truckers and carriers
CMS warned Mylan about EpiPen rebate issues multiple times